ATVB:COVID-19肺炎和社区获得性肺炎患者静脉血栓栓塞风险比较

2020-07-14 MedSci原创 MedSci原创

该研究的结果表明COVID-19肺炎与高凝状态有关。但是,COVID-19肺炎患者的VTE发生率并未明显高于CAP患者。

近日,血管领域权威杂志Arteriosclerosis, Thrombosis, and Vascular Biology上发表了一篇研究文章,该研究旨在探究和比较新型冠状病毒病2019(COVID-19)肺炎和社区获得性肺炎(CAP)患者静脉血栓栓塞(VTE)的风险和发生率。

研究人员回顾性地分析了2020年1月1日至3月23日期间湖北宜昌市中心人民医院住院的616例肺炎患者的病历。COVID-19肺炎患者在COVID-19定点医院接受治疗,而CAP患者则被送往常规医院接受治疗。研究人员使用帕多瓦预测评分评估了VTE风险。所有患者均接受药物或机械性VTE预防治疗。VTE是通过Duplex超声或计算机断层扫描肺血管造影诊断的。研究人员统计并比较了COVID-19和CAP组之间的差异。所有统计检验均为双侧检验,P<0.05被认为具有统计学意义。

在616名患者中,有256名患有COVID-19肺炎,有360名患有CAP。COVID-19肺炎组的VTE总发生率为2%和CAP组为3.6%(P=0.229)。15.6%的COVID-19肺炎患者和10%的CAP患者被归类为VTE高风险(Padua评分>4),差异显著(P=0.036)。在那些高危患者中,COVID-19肺炎组的VTE发生率为12.5%,CAP组的VTE发生率为16.7%(P=0.606)。重症患者的亚组分析显示,COVID-19组的VTE率为6.7%,而CAP组为13%(P=0.484)。COVID-19组和CAP组的院内死亡率分别为6.3%和3.9%(P=0.180)。

该研究的结果表明COVID-19肺炎与高凝状态有关。但是,COVID-19肺炎患者的VTE发生率并未明显高于CAP患者。

原始出处:

Fei Mei.et al.Comparison of Venous Thromboembolism Risks Between COVID-19 Pneumonia and Community-Acquired Pneumonia Patients.ATVB.2020.https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.314779

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-12-01 gongliu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2021-04-15 fusion
  6. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2021-06-10 xue8602
  7. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]
    2020-07-20 ms 内分泌科张

    学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1770098, encodeId=76c81e7009893, content=<a href='/topic/show?id=14b99918664' target=_blank style='color:#2F92EE;'>#静脉血栓栓塞风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99186, encryptionId=14b99918664, topicName=静脉血栓栓塞风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b79338139346, createdName=ymljack, createdTime=Sun Nov 08 10:35:29 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042664, encodeId=4ffd20426640e, content=<a href='/topic/show?id=999c88014ea' target=_blank style='color:#2F92EE;'>#获得性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88014, encryptionId=999c88014ea, topicName=获得性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d4b7363, createdName=pandamao2010, createdTime=Mon Aug 17 14:35:29 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078462, encodeId=e68d20e84621f, content=<a href='/topic/show?id=1842100886df' target=_blank style='color:#2F92EE;'>#风险比#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100886, encryptionId=1842100886df, topicName=风险比)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Sat Feb 13 07:35:29 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977981, encodeId=381f19e7981ff, content=<a href='/topic/show?id=20411e958de' target=_blank style='color:#2F92EE;'>#TVB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17958, encryptionId=20411e958de, topicName=TVB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Tue Dec 01 10:35:29 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1698117, encodeId=72b9169811e81, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Thu Apr 15 19:35:29 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955498, encodeId=8b5f19554980b, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Jun 10 17:35:29 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803409, encodeId=92f2803409c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201214/b3170121d995432ea306ae3a7809cc05/2cfb236f361b4d3c80ef8fdef4301832.jpg, createdBy=8ad35400531, createdName=ms 内分泌科张, createdTime=Mon Jul 20 02:00:24 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395874, encodeId=6a8213958e4c8, content=<a href='/topic/show?id=7a89e4036eb' target=_blank style='color:#2F92EE;'>#社区#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74036, encryptionId=7a89e4036eb, topicName=社区)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Thu Jul 16 13:35:29 CST 2020, time=2020-07-16, status=1, ipAttribution=)]

相关资讯

Chest:不发热社区获得性肺炎患者菌血症的发生率和预测因素

由此可见,相当部分的细菌性CAP患者并不发热。与高热菌血症或非细菌性肺炎患者相比,这些患者的死亡率增加。因此,发热作为BC必要性指标的相关性值得重新考虑。

社区获得性肺炎也能要命,治疗要快准狠!

患者男性,27岁, 5月2日急诊就诊。

Chest:社区获得性肺炎患者通过心脏生物标志物识别的早期和晚期心血管事件风险

由此可见,心脏生物标志物可用于确定高风险的早期和晚期心血管事件的CAP患者。他们可能有助于个性化治疗优化和设计未来的干预性研究,以降低心血管风险。

Eur Respir J:广谱抗生素使用与社区获得性肺炎患者不良结局的关系

由此可见,广谱抗生素似乎与社区获得性肺炎患者的死亡率增加和其他不良结局相关。

Eur Respir J:非流感病毒所致成人社区获得性肺炎病情严重程度与预后——一项来自CAP-China中国肺炎研究网的前瞻性注册登记研究

本研究比较了非免疫抑制成人流感与非流感病毒所致 CAP 的病情严重程度、达临床稳定时间、并发症、病死率及住院时间等,首次系统性评估了成人非流感病毒肺炎的临床意义,研究论文 2019 年 6 月 4 日在欧洲呼吸杂志在线发表。

XENLETA(lefamulin)治疗社区获得性肺炎(CAP):欧盟CHMP持积极意见

社区获得性肺炎(community-acquired pneumonia, CAP)是全球发病和死亡的主要原因。